New York, NY -- (SBWIRE) -- 12/17/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Novavax, Inc.(NASDAQ:NVAX), J.C. Penney Company, Inc.(NYSE:JCP), Annaly Capital Management, Inc.(NYSE:NLY), NuPathe Inc(NASDAQ:PATH).
Novavax, Inc.(NASDAQ:NVAX) showed a volume of 6,620 shares by the end of last trade whereas the average volume of the stock remained 4.43 million shares. The stock opened the session at $3.87 but then moved to $4.61. Novavax, Inc. (Novavax) is a clinical stage biopharmaceutical company. The Company focuses on developing recombinant vaccines. The Company’s technology platform is based on recombinant vaccine technology that includes the virus-like particles (VLPs).
Is WMT a Solid Investment at These Levels? Read This Report For Details
J.C. Penney Company, Inc.(NYSE:JCP) opened the session at $8.67 and closed the session at $8.48. The stock showed a negative performance of -1.05% in previous trading session.Traded with volume of 100 shares in the prior session and the average volume of the stock remained 38.61 million shares. J. C. Penney Company, Inc. is a holding company whose principal operating subsidiary is J. C. Penney Corporation, Inc. (JCP).
Has JCP Found The Bottom And Ready To Gain Momentum? Find Out Here
Annaly Capital Management, Inc.(NYSE:NLY) opened the session at $9.94 and closed the session at $9.82. The stock showed a negative performance of -1.21% in previous trading session.Traded with volume of 200 shares in the prior session and the average volume of the stock remained 15.19 million shares. The beta of the stock remained 0.31. Annaly Capital Management, Inc. (Annaly) owns, manage, and finance a portfolio of real estate related investments, including mortgage pass-through certificates, collateralized mortgage obligations (CMOs), Agency callable debentures, and other securities representing interests in or obligations backed by pools of mortgage loans. The Company's wholly owned subsidiaries offer diversified real estate, asset management and other financial services.
Why Should Investors Buy NLY After the Recent Fall? Just Go Here and Find Out
NuPathe Inc(NASDAQ:PATH) Traded with volume of 8,060 shares in the prior session and the average volume of the stock remained 625,920 shares. The beta of the stock remained 2.96. NuPathe, Inc. develops therapeutics for diseases of the central nervous system including neurological and psychiatric disorders. The Companys products are NP201 for the continuous symptomatic treatment of Parkinson's disease and NP202 for the long-term treatment of schizophrenia and bipolar disorder.
Will PATH Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)